SRK 001
Alternative Names: SRK-001Latest Information Update: 28 Jan 2025
At a glance
- Originator Eli Lilly and Company
- Developer Sarkana Pharma
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus(In volunteers) in Netherlands (IV)
- 09 Mar 2023 Sarkana Pharma terminates a phase I trial in Systemic lupus erythematosus (In volunteers) in the Netherlands (IV) due to occurrence of eye related adverse events (NCT05156034)
- 21 Dec 2021 Phase-I clinical trials in Systemic lupus erythematosus (In volunteers) in Netherlands (IV) (NCT05156034)